IGFBP3 siRNA (h) from Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

(1) Integrated multi-omics profiling to establish an IGFBP-based prognostic score for pancreatic ductal adenocarcinoma: unraveling prognostic biomarkers, immune microenvironment crosstalk, and therapeutic implicationsFront ImmunolMay 15, 2025Xiao Guan, Yongrun Mu, Xin Jin, Chengfeng WangT cell migration assays PANC-1 with IGFBP3-knockdown generated via siRNA (Santa cruz biotechnology, sc-39587) were cultured in DMEM supplemented with 10% fetal bovine serum under standard conditions (37°C, 5%

(2) Differential effect of cancer-associated fibroblast-derived extracellular vesicles on cisplatin resistance in oral squamous cell carcinoma via miR-876-3pTheranosticsJanuary 1, 2024Kang SH, Oh SY, Lee KY, Lee HJ, Kim MS, Kwon TG, Kim JW, Lee ST, Choi SY, Hong SH.(MC12886) and antagomir (AM12886) of miR-876-3p were purchased from Thermo Fisher Scientific (USA). IGFBP3 (sc-39587) and GATA1 (sc-35452) siRNA mixture containing 2-3 specific oligonucleotides were purchased from Santa Cruz Biotechnology

IGFBP3 siRNA (h)